J. Chad Hoyle

Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study

James F. Howard, Kimiaki Utsugisawa, Michael Benatar et al. · The Lancet Neurology · 2017 · 745 citations

Multicentre Study, Pharmacology, Medicine +3

Safety and Efficacy of Omaveloxolone in Friedreich Ataxia (<scp>MOXIe</scp> Study)

David R. Lynch, Melanie Chin, Martin B. Delatycki et al. · Annals of Neurology · 2020 · 273 citations · Full text

Efficacy of Omaveloxolone in Friedreich's Ataxia: <scp>Delayed‐Start</scp> Analysis of the <scp>MOXIe</scp> Extension

David R. Lynch, Melanie Chin, Sylvia Boesch et al. · Movement Disorders · 2022 · 105 citations · Full text

Psychometric properties of the Friedreich Ataxia Rating Scale

Christian Rummey, Louise A. Corben, Martin B. Delatycki et al. · Neurology Genetics · 2019 · 86 citations · Full text

Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension

Renato Mantegazza, Gil I. Wolfe, Srikanth Muppidi et al. · Neurology · 2020 · 74 citations · Full text